FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3018754145> ?p ?o ?g. }

• W3018754145 abstract "Glutaminase (GA) catalyzes the first step in mitochondrial glutaminolysis playing a key role in cancer metabolic reprogramming. Humans express two types of GA isoforms: GLS and GLS2. GLS isozymes have been consistently related to cell proliferation, but the role of GLS2 in cancer remains poorly understood. GLS2 is repressed in many tumor cells and a better understanding of its function in tumorigenesis may further the development of new therapeutic approaches. We analyzed GLS2 expression in HCC, GBM and neuroblastoma cells, as well as in monkey COS-7 cells. We studied GLS2 expression after induction of differentiation with phorbol ester (PMA) and transduction with the full-length cDNA of GLS2. In parallel, we investigated cell cycle progression and levels of p53, p21 and c-Myc proteins. Using the baculovirus system, human GLS2 protein was overexpressed, purified and analyzed for posttranslational modifications employing a proteomics LC-MS/MS platform. We have demonstrated a dual targeting of GLS2 in human cancer cells. Immunocytochemistry and subcellular fractionation gave consistent results demonstrating nuclear and mitochondrial locations, with the latter being predominant. Nuclear targeting was confirmed in cancer cells overexpressing c-Myc- and GFP-tagged GLS2 proteins. We assessed the subnuclear location finding a widespread distribution of GLS2 in the nucleoplasm without clear overlapping with specific nuclear substructures. GLS2 expression and nuclear accrual notably increased by treatment of SH-SY5Y cells with PMA and it correlated with cell cycle arrest at G2/M, upregulation of tumor suppressor p53 and p21 protein. A similar response was obtained by overexpression of GLS2 in T98G glioma cells, including downregulation of oncogene c-Myc. Furthermore, human GLS2 was identified as being hypusinated by MS analysis, a posttranslational modification which may be relevant for its nuclear targeting and/or function. Our studies provide evidence for a tumor suppressor role of GLS2 in certain types of cancer. The data imply that GLS2 can be regarded as a highly mobile and multilocalizing protein translocated to both mitochondria and nuclei. Upregulation of GLS2 in cancer cells induced an antiproliferative response with cell cycle arrest at the G2/M phase." @default.
• W3018754145 created "2020-05-01" @default.
• W3018754145 creator A5002088132 @default.
• W3018754145 creator A5003590248 @default.
• W3018754145 creator A5004832556 @default.
• W3018754145 creator A5010111011 @default.
• W3018754145 creator A5013818971 @default.
• W3018754145 creator A5016233665 @default.
• W3018754145 creator A5018624790 @default.
• W3018754145 creator A5031560696 @default.
• W3018754145 creator A5037725582 @default.
• W3018754145 creator A5038340796 @default.
• W3018754145 creator A5039428378 @default.
• W3018754145 creator A5052134873 @default.
• W3018754145 creator A5054962431 @default.
• W3018754145 creator A5065818932 @default.
• W3018754145 creator A5072494699 @default.
• W3018754145 creator A5074214258 @default.
• W3018754145 creator A5075597784 @default.
• W3018754145 creator A5084561391 @default.
• W3018754145 creator A5088576349 @default.
• W3018754145 creator A5090145725 @default.
• W3018754145 creator A5091731381 @default.
• W3018754145 date "2020-02-10" @default.
• W3018754145 modified "2023-10-15" @default.
• W3018754145 title "Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation" @default.
• W3018754145 hasPublicationYear "2020" @default.
• W3018754145 type Work @default.
• W3018754145 sameAs 3018754145 @default.
• W3018754145 citedByCount "0" @default.
• W3018754145 crossrefType "journal-article" @default.
• W3018754145 hasAuthorship W3018754145A5002088132 @default.
• W3018754145 hasAuthorship W3018754145A5003590248 @default.
• W3018754145 hasAuthorship W3018754145A5004832556 @default.
• W3018754145 hasAuthorship W3018754145A5010111011 @default.
• W3018754145 hasAuthorship W3018754145A5013818971 @default.
• W3018754145 hasAuthorship W3018754145A5016233665 @default.
• W3018754145 hasAuthorship W3018754145A5018624790 @default.
• W3018754145 hasAuthorship W3018754145A5031560696 @default.
• W3018754145 hasAuthorship W3018754145A5037725582 @default.
• W3018754145 hasAuthorship W3018754145A5038340796 @default.
• W3018754145 hasAuthorship W3018754145A5039428378 @default.
• W3018754145 hasAuthorship W3018754145A5052134873 @default.
• W3018754145 hasAuthorship W3018754145A5054962431 @default.
• W3018754145 hasAuthorship W3018754145A5065818932 @default.
• W3018754145 hasAuthorship W3018754145A5072494699 @default.
• W3018754145 hasAuthorship W3018754145A5074214258 @default.
• W3018754145 hasAuthorship W3018754145A5075597784 @default.
• W3018754145 hasAuthorship W3018754145A5084561391 @default.
• W3018754145 hasAuthorship W3018754145A5088576349 @default.
• W3018754145 hasAuthorship W3018754145A5090145725 @default.
• W3018754145 hasAuthorship W3018754145A5091731381 @default.
• W3018754145 hasConcept C109549099 @default.
• W3018754145 hasConcept C119795356 @default.
• W3018754145 hasConcept C121608353 @default.
• W3018754145 hasConcept C153911025 @default.
• W3018754145 hasConcept C181199279 @default.
• W3018754145 hasConcept C2779349466 @default.
• W3018754145 hasConcept C29537977 @default.
• W3018754145 hasConcept C502942594 @default.
• W3018754145 hasConcept C515207424 @default.
• W3018754145 hasConcept C54355233 @default.
• W3018754145 hasConcept C55493867 @default.
• W3018754145 hasConcept C555283112 @default.
• W3018754145 hasConcept C62112901 @default.
• W3018754145 hasConcept C86803240 @default.
• W3018754145 hasConcept C96232424 @default.
• W3018754145 hasConceptScore W3018754145C109549099 @default.
• W3018754145 hasConceptScore W3018754145C119795356 @default.
• W3018754145 hasConceptScore W3018754145C121608353 @default.
• W3018754145 hasConceptScore W3018754145C153911025 @default.
• W3018754145 hasConceptScore W3018754145C181199279 @default.
• W3018754145 hasConceptScore W3018754145C2779349466 @default.
• W3018754145 hasConceptScore W3018754145C29537977 @default.
• W3018754145 hasConceptScore W3018754145C502942594 @default.
• W3018754145 hasConceptScore W3018754145C515207424 @default.
• W3018754145 hasConceptScore W3018754145C54355233 @default.
• W3018754145 hasConceptScore W3018754145C55493867 @default.
• W3018754145 hasConceptScore W3018754145C555283112 @default.
• W3018754145 hasConceptScore W3018754145C62112901 @default.
• W3018754145 hasConceptScore W3018754145C86803240 @default.
• W3018754145 hasConceptScore W3018754145C96232424 @default.
• W3018754145 hasLocation W30187541451 @default.
• W3018754145 hasOpenAccess W3018754145 @default.
• W3018754145 hasPrimaryLocation W30187541451 @default.
• W3018754145 hasRelatedWork W1978100148 @default.
• W3018754145 hasRelatedWork W1978915307 @default.
• W3018754145 hasRelatedWork W1981401255 @default.
• W3018754145 hasRelatedWork W1992318779 @default.
• W3018754145 hasRelatedWork W1997306291 @default.
• W3018754145 hasRelatedWork W2004372671 @default.
• W3018754145 hasRelatedWork W2049503488 @default.
• W3018754145 hasRelatedWork W2062349989 @default.
• W3018754145 hasRelatedWork W2136143011 @default.
• W3018754145 hasRelatedWork W2269870164 @default.
• W3018754145 hasRelatedWork W2280789909 @default.
• W3018754145 hasRelatedWork W2306380257 @default.
• W3018754145 hasRelatedWork W2549285612 @default.
• W3018754145 hasRelatedWork W2588688173 @default.
• W3018754145 hasRelatedWork W2727666597 @default.

• next